NASDAQ
HSCS
Last Price
US $2.62
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
HeartSciences Inc. cash flow to debt ratio of 629.47% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial stability - Healthy cash flow growth.
HeartSciences Inc.'s free cash flow has increased -248.83% from $-6.20M last year to $9.22M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
HeartSciences Inc.'s debt to equity ratio is 1.46, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
HeartSciences Inc.'s debt has increased relative to shareholder equity from 0.14 last year to 1.46 today, signaling weakened financials
Financial stability - Net debt/EBITDA.
HeartSciences Inc. has a net debt to EBITDA ratio of 0.12x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial risk - ICR.
Interest expense is not separately reported in HeartSciences Inc.'s latest filing, so interest coverage cannot be calculated.
Financial stability - Profit margin growth.
HeartSciences Inc.'s profit margin has increased (-99.99%) in the last year from -201.50K% to -14.16%, signaling increasing performance
Financial risk - Short term assets vs short term liabilities.
HeartSciences Inc.'s short-term liabilities of $3.70M exceed its short-term assets of $2.17M, signaling financial risk
Decreasing performance - ROA.
HeartSciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
HeartSciences Inc.'s return on equity of -498.03%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
HeartSciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
HeartSciences Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
HeartSciences Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
HeartSciences Inc. has a free cash flow yield of 162.39%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
HeartSciences Inc.'s yearly earnings has decreased 44.62% since last year from $-8.77M to $-12.68M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
HeartSciences Inc.'s yearly revenue has decreased -76.61% since last year from $18.60K to $4.35K, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -195.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
HeartSciences Inc.'s 3-year revenue CAGR of 2.49K% is positive, indicating growing revenue over the past 3 years
Decreasing performance - Revenue consistency.
HeartSciences Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
HeartSciences Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
HeartSciences Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
HeartSciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
HeartSciences Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
HeartSciences Inc. has an EV/EBITDA ratio of 0.47x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
HeartSciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
HeartSciences Inc. has a price-to-book ratio of 3.12x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
HeartSciences Inc. has a price-to-sales ratio of 0.09x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-233.04%
Return on equity
ROIC: -285.43%
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $2.62
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.